Backed by GV.
About the role
Playing a critical role as a lead statistician for clinical program(s) and studies in clinical late-stage development and the subject matter expert (SME) in Biostatistics within Quantitative Sciences function, this position is to provide statistical leadership and support for clinical development strategy and clinical studies through product life cycle. Provide statistical support and strategic input to clinical development plans, proof of concept criteria, and team’s preparation for company governance reviews.
What they're looking for
- Active participation in NDA/BLA filing through label negotiations is desirable
More about this role
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
Playing a critical role as a lead statistician for clinical program(s) and studies in clinical late-stage development and the subject matter expert (SME) in Biostatistics within Quantitative Sciences function, this position is to provide statistical leadership and support for clinical development strategy and clinical studies through product life cycle.
Provide statistical support and strategic...
Browse similar: Startup jobs · San Francisco Bay Area